• SPX
  • $5,751.07
  • 0.9 %
  • $51.13
  • DJI
  • $42,352.75
  • 0.81 %
  • $341.16
  • N225
  • $38,635.62
  • 0.22 %
  • $83.56
  • FTSE
  • $8,280.63
  • -0.02 %
  • -$1.89
  • IXIC
  • $18,137.85
  • 1.22 %
  • $219.38
Viatris Inc. (VTRS) Stock Price, News & Analysis

Viatris Inc. (VTRS) Stock Price, News & Analysis

Currency in USD Disclaimer

$11.59

$0.16

(1.36%)

Day's range
$11.48
Day's range
$11.65
50-day range
$10.85
Day's range
$12.77
  • Country: US
  • ISIN: US92556V1061
52 wk range
$8.74
Day's range
$13.62


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.93
  • Piotroski Score 5.00
  • Grade Neutral
  • Symbol (VTRS)
  • Company Viatris Inc.
  • Price $11.59
  • Changes Percentage (1.36%)
  • Change $0.16
  • Day Low $11.48
  • Day High $11.65
  • Year High $13.62

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

  • Last Earnings 08/05/2024
  • Ex-Dividend for 5/16 Dividend 08/23/2024
  • Dividend Payable 09/13/2024
  • Today N/A
  • Next Earnings (Estimated) 11/06/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $14.00
  • High Stock Price Target $15.00
  • Low Stock Price Target $12.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.05
  • Trailing P/E Ratio -209.4
  • Forward P/E Ratio -209.4
  • P/E Growth -209.4
  • Net Income $54.70 M

Income Statement

Quarterly

Annual

Latest News of VTRS

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

  • Decoding Viatris Inc (VTRS): A Strategic SWOT Insight

    Viatris Inc reported a decline in net sales and a shift to a net loss in its recent financial report. Despite challenges, the company's global reach and diverse portfolio offer strengths. Strategic di...

    By Yahoo! Finance | 1 month ago
Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.